Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT04475510
NA
Discontinuation of Antithrombotic Treatment Following Patent Foramen Ovale Closure in Young Patients With Cryptogenic Stroke
Sponsor: Josep Rodes-Cabau
View on ClinicalTrials.gov
Summary
To determine the safety of antithrombotic treatment discontinuation 12 months following successful transcatheter PFO closure.
Official title: Discontinuation of Antithrombotic Treatment Following Patent Foramen Ovale Closure in Young Patients With Cryptogenic Stroke. The HALTI Trial
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2020-07-08
Completion Date
2032-08-01
Last Updated
2026-03-24
Healthy Volunteers
Yes
Interventions
OTHER
Antiplatelet treatment discontinuation
All patients will undergo a clinical evaluation and cerebral MRI at 12 months (before antiplatelet treatment cessation) and at 24 months post-PFO closure.
Locations (1)
IUCPQ
Québec, Quebec, Canada